Advancing Non-Invasive Healthcare
In 2015 Nonacus was founded with a singular purpose: to offer high quality, non-invasive, genetic testing with the end-user at the forefront. Formed by a dedicated group of biotechnology professionals with over 35 years of experience within the sector, Nonacus understands the need for laboratories to continually deliver progress. This understanding forms the basis of all our products and drives our innovation.
Our Mission and Purpose
Our goal is to democratize non-invasive genetic testing globally with a focus on oncology so that we can enable decentralized, cost-effective and cutting-edge cancer detection and longitudinal patient monitoring.
Detecting cancer earlier and informing patient outcomes through the deployment of a truly innovative liquid biopsy testing platform.
The Nonacus Name
When Chris and Lee founded Nonacus in 2015 they had a singular purpose - to develop non-invasive DNA tests that would change the way genomic diagnostics was done.
Choosing a name that would reflect this mission wasn't easy.
Based off the Latin term ‘non acus’ meaning ‘no needle’, Nonacus accurately symbolises the company’s mission- to move away from intrusive, risky diagnostic procedures like tissue biopsies or amniocentesis towards less invasive testing. To read more about the story behind the name click here.
Read Our Latest Insights
Genetic testing company, Nonacus, has launched its latest next generation sequencing (NGS) test in the GALEAS product range – the GALEAS Hereditary Plus panel – which provides laboratories and clinicians with a comprehensive and streamlined way to diagnose patients with cancer that is caused by inherited genetic mutations.Read More
Hereditary cancer testing has become a valuable tool in healthcare, contributing to the understanding and identification of individuals’ susceptibility to cancer.Read More